The HERTHENA-Lung01 Phase 2 Trial showed that Patritumab Deruxtecan brought about meaningful and durable effects in Patients with non-small cell lung cancer.

This article summarized the latest R&D progress of Perphenazine, the Mechanism of Action for Perphenazine, and the drug target R&D trends for Perphenazine.

CD38 is a multifunctional enzyme found on the surface of various cells in the human body, including immune cells and certain tissues.

This article summarized the latest R&D progress of Oxybutynin Chloride, the Mechanism of Action for Oxybutynin Chloride, and the drug target R&D trends for Oxybutynin Chloride.

Samsung Bioepis Co., Ltd. disclosed it has struck a commercialization pact with Sandoz regarding SB17, a potential biosimilar to Stelarai(ustekinumab).

This article summarized the latest R&D progress of Nitazoxanide, the Mechanism of Action for Nitazoxanide, and the drug target R&D trends for Nitazoxanide.

OKYO Pharma Limited has successfully enrolled its patient quota for the Phase 2 clinical trial.

This article summarized the latest R&D progress of Methylene blue, the Mechanism of Action for Methylene blue, and the drug target R&D trends for Methylene blue.

This article summarized the latest R&D progress of Methyl Salicylate, the Mechanism of Action for Methyl Salicylate, and the drug target R&D trends for Methyl Salicylate.

This article summarized the latest R&D progress of Meropenem, the Mechanism of Action for Meropenem, and the drug target R&D trends for Meropenem.

Carrick Therapeutics made an announcement that their IND application for CT7439 has been given the green light by U.S FDA.

This article summarized the latest R&D progress of Meprobamate, the Mechanism of Action for Meprobamate, and the drug target R&D trends for Meprobamate.